Loading stock data…
Adagene Inc (ADAG)
$4.15-0.04 (-0.95%)
Market OpenUpdated 2:05 PM EDT
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adagene Inc. in the Healthcare sector is trading at $4.15 with a market capitalization of $235M. Wall Street consensus targets $9.40 (5 analysts), implying a +126.5% move over the next 12 months. The stock is currently near its 52-week high of $4.75, remaining 50.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +126.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$235.22M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
77,575
Recent News
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company’s focus on improving the therapeutic index of CTLA-4 inhibition
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money. Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration with Incyte Corp. (NASDAQ:INCY) to evaluate a novel combination therapy for microsatellite stable colorectal cancer/MSS CRC. The study […]
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed?
In late March and early April 2026, Incyte reported positive 54-week Phase 3 data for its JAK1 inhibitor povorcitinib in hidradenitis suppurativa and Adagene announced entering a clinical collaboration with Incyte to test a combination immunotherapy regimen in advanced microsatellite stable colorectal cancer. Together with recent leadership changes, these developments highlight Incyte’s push to build a broader immunology and oncology franchise around both late-stage and early pipeline...